Arcus Biosciences (RCUS) – Research Analysts’ Weekly Ratings Changes

Share on StockTwits

Several brokerages have updated their recommendations and price targets on shares of Arcus Biosciences (NYSE: RCUS) in the last few weeks:

  • 11/19/2019 – Arcus Biosciences was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company’s product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA. “
  • 11/12/2019 – Arcus Biosciences is now covered by analysts at SunTrust Banks, Inc.. They set a “buy” rating and a $20.00 price target on the stock.
  • 11/11/2019 – Arcus Biosciences had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $22.00 price target on the stock.
  • 11/7/2019 – Arcus Biosciences was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company’s product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA. “
  • 10/20/2019 – Arcus Biosciences had its “buy” rating reaffirmed by analysts at Mizuho.
  • 10/4/2019 – Arcus Biosciences was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company’s product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA. “
  • 10/3/2019 – Arcus Biosciences was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $9.75 price target on the stock. According to Zacks, “Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company’s product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA. “
  • 9/26/2019 – Arcus Biosciences is now covered by analysts at Mizuho. They set a “buy” rating and a $22.00 price target on the stock.

RCUS traded up $0.19 during trading on Thursday, reaching $7.97. 82,200 shares of the company traded hands, compared to its average volume of 170,320. Arcus Biosciences Inc has a 12-month low of $6.30 and a 12-month high of $13.77. The firm has a fifty day simple moving average of $8.11 and a 200 day simple moving average of $8.38. The company has a market cap of $350.82 million, a P/E ratio of -5.57 and a beta of 0.99.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.02). Arcus Biosciences had a negative net margin of 1,180.37% and a negative return on equity of 38.73%. The company had revenue of $1.75 million for the quarter, compared to analysts’ expectations of $1.34 million. On average, equities research analysts predict that Arcus Biosciences Inc will post -2.2 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the business. Athanor Capital LP purchased a new stake in Arcus Biosciences during the 2nd quarter valued at approximately $126,000. GSA Capital Partners LLP grew its holdings in shares of Arcus Biosciences by 17.3% in the second quarter. GSA Capital Partners LLP now owns 16,243 shares of the company’s stock valued at $129,000 after purchasing an additional 2,392 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Arcus Biosciences by 22.1% in the second quarter. BlackRock Inc. now owns 2,236,133 shares of the company’s stock valued at $17,777,000 after purchasing an additional 404,432 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Arcus Biosciences by 5.5% in the second quarter. JPMorgan Chase & Co. now owns 515,262 shares of the company’s stock valued at $3,983,000 after purchasing an additional 26,709 shares in the last quarter. Finally, White Pine Investment CO purchased a new position in shares of Arcus Biosciences in the second quarter valued at $151,000. 49.01% of the stock is owned by institutional investors and hedge funds.

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.

Featured Story: Return on Equity (ROE)

Receive News & Ratings for Arcus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.